Bowen’s disease is a form of skin cancer that stays confined to the outermost layer of the skin, classified medically as squamous cell carcinoma in situ.1PubMed Central. Bowen’s Disease Because the abnormal cells have not pushed past the boundary between the epidermis and the tissue beneath it, the condition sits in a gray zone: it is technically cancer, but it behaves far less aggressively than the invasive squamous cell carcinomas most people picture when they hear the word. That distinction matters for treatment decisions and outlook, though the picture is more nuanced than a clean “pre-cancer vs. cancer” label suggests.
What It Looks Like and Where It Shows Up
Bowen’s disease typically appears as a persistent, slowly growing red or pink patch with a scaly or crusty surface. The patch is usually flat or only slightly raised, and it can be mistaken for eczema, psoriasis, or a fungal infection because it does not look dramatically “cancerous.” It tends to be well-defined at its edges but may grow to several centimeters across if left alone. Itching or tenderness is possible but not universal; many people notice the patch only because it does not go away with moisturizer or over-the-counter creams.
A large study analyzing over 1,000 cases found that the head and neck were the most common site, followed by the lower limbs and then the upper limbs. The torso was the least common location. There were clear sex-based differences in where lesions appeared: roughly three-quarters of lower-limb cases were in women, while about four-fifths of scalp and ear cases were in men.2Journal of the American Academy of Dermatology. Cutaneous Bowen’s disease: An analysis of 1001 cases according to age, sex, and site These patterns track with sun-exposure habits: men are more likely to have thinning hair exposing the scalp, while women’s lower legs receive cumulative UV over a lifetime of skirts and shorts. Bowen’s disease can also appear on the genitals and around the anus, where UV exposure is not a factor and other causes come into play.
What Causes It
Chronic sun exposure is the most common driver, which explains why the condition is far more frequent in fair-skinned people over 60. But UV is not the only route. Several other factors can trigger or contribute to the disease, and understanding them matters because they influence where and how aggressively the condition behaves.
Arsenic exposure is a well-documented cause. A case report described a 35-year-old mine worker who developed Bowen’s disease on his thigh after 15 years of workplace and drinking-water arsenic exposure.3PubMed Central. Arsenic-related Bowen’s disease, palmar keratosis, and skin cancer Arsenic-related cases are especially concerning because they tend to produce multiple patches rather than a single one, and in a study of Chinese patients with chronic arsenic poisoning and skin manifestations, about 70% had between two and ten lesions, and roughly 40% also had invasive squamous cell carcinomas.4Formosan Journal of Surgery. Multiple Bowen’s disease and epithelioid malignant peripheral nerve sheath tumor in a patient who experienced chronic arsenic poisoning In regions where arsenic contamination of groundwater is a known problem, Bowen’s disease can appear at younger ages and in unusual locations that get little sun.
Human papillomavirus (HPV) infection has been linked to Bowen’s disease as well, particularly in genital and nail-area cases. High-risk HPV strains such as HPV-16 have been detected in nail-unit Bowen’s disease, and a review of published cases found a clear association between HPV-positive Bowen’s disease and high-risk HPV types.5PubMed. High-risk human papillomavirus infection in Bowen’s disease of the nail unit: report of three cases and review of the literature Rarer strains have also been implicated: one case report documented HPV-34 in a finger lesion with an unusual skip pattern, where the cancerous area was discontinuous rather than a single solid patch.6PubMed Central. Multiple Bowen’s disease on the finger associated with human papillomavirus type 34
People with suppressed immune systems, whether from organ transplants, HIV, or immunosuppressive medications, face a heightened risk. Bowen’s disease in immunocompromised patients is more likely to appear as multiple lesions at once and to behave more aggressively than in people with intact immune function.7PubMed. Variations in presentation of squamous cell carcinoma in situ (Bowen’s disease) in immunocompromised patients This population often needs closer follow-up and more aggressive treatment than the standard approach.
How It Is Diagnosed
The definitive diagnosis requires a skin biopsy, where a small sample of tissue is examined under a microscope. However, the initial suspicion often comes from the clinical appearance, and non-invasive tools are increasingly used to narrow down the diagnosis before committing to a biopsy.
Dermoscopy, which uses a magnifying lens with polarized light, reveals several characteristic features in Bowen’s disease: coiled “glomerular” blood vessels and a scaly surface are the most consistent findings.8PubMed. Dermoscopy of Bowen’s disease These patterns help distinguish it from eczema, psoriasis, and superficial basal cell carcinoma, all of which can look similar to the naked eye. Reflectance confocal microscopy (RCM), a newer technique that images the skin at near-cellular resolution without cutting, can also aid diagnosis. RCM shows characteristic “targetoid” cells in the thickened epidermis that correspond to the abnormal cells seen on biopsy.9PubMed Central. Non-invasive imaging techniques for the in vivo diagnosis of Bowen’s disease: Three case reports Both dermoscopy and RCM are also useful for monitoring lesions after non-surgical treatment, since they can pick up residual disease without repeated biopsies.
One diagnostic pitfall worth noting: in a series of Bowen’s disease cases treated with Mohs surgery, about 20% had been initially misdiagnosed as basal cell carcinoma or invasive squamous cell carcinoma.10PubMed. Cutaneous squamous carcinoma in situ (Bowen’s disease): treatment with Mohs micrographic surgery Misdiagnosis in either direction matters: underestimating the condition means missing cancer, while overestimating it can lead to unnecessarily aggressive treatment.
The Pigmented Variant
Most Bowen’s disease appears as a reddish or pink scaly patch, but a rare form shows up with brown or dark pigmentation instead. Pigmented Bowen’s disease accounts for less than 2% of all cases and can be confused with melanoma, seborrheic keratosis, or other pigmented skin conditions.11PubMed Central. A Case of Pigmented Bowen’s Disease The pigmentation comes from extra melanin deposited in and below the epidermis on top of the usual in-situ carcinoma changes. Cases have been reported on the face and neck as expected from sun exposure, but also on the trunk, extremities, and anogenital area.12PubMed. Clinical and dermoscopic features of genital pigmented Bowen disease On dermoscopy, pigmented Bowen’s disease shows small brown globules or a uniform brown tint alongside the glomerular vessels seen in typical cases, which helps differentiate it from melanoma even before biopsy.
Risk of Progression to Invasive Cancer
The central clinical question with Bowen’s disease is whether and how often it breaks through the basement membrane and becomes invasive squamous cell carcinoma. The widely cited figure is a 3-to-5% lifetime risk of progression.13PubMed Central. Development of poorly differentiated invasive squamous cell carcinoma in giant Bowen’s disease: a case report with dermatoscopy Once invasion occurs, roughly a third of those invasive tumors may go on to spread to other parts of the body. That combination, low overall progression risk but real danger once invasion happens, underpins the standard recommendation to treat Bowen’s disease rather than simply watch it.
However, the 3-to-5% figure may underestimate the true rate. A 2017 study of 566 biopsy-confirmed Bowen’s disease cases found that 16.3% already had squamous cell carcinoma when the lesion was surgically removed, a figure considerably higher than traditional estimates.14BMJ. Bowen’s disease The discrepancy may reflect sampling limitations in the older studies: a small punch biopsy can confirm in-situ disease in one area while missing an invasive component elsewhere in the same lesion. Excising the full patch and examining all of it turns up more invasion than spot-checking does. This finding does not mean that every Bowen’s disease patch is a ticking bomb, but it does reinforce the argument for treatment rather than a wait-and-see approach.
For arsenic-related Bowen’s disease specifically, molecular markers may help predict which lesions are most likely to progress. Research on arsenic-exposed patients found that certain DNA abnormalities in the tumor cells, particularly a pattern of altered methylation at specific sites in the cyclin D1 gene promoter, were strongly associated with subsequent development of invasive cancer.15PubMed. Cyclin D1 promoter -56 and -54bp CpG un-methylation predicts invasive progression in arsenic-induced Bowen’s disease Patients whose specimens showed normal DNA histograms developed no invasive cancers at all, while those with the most abnormal DNA patterns had the highest invasion rates. This kind of risk stratification is not yet routine in clinical practice, but it points toward a future where treatment intensity can be tailored to the molecular profile of each lesion.
Treatment Options
Because Bowen’s disease has not yet invaded deeper tissue, the range of effective treatments is broad, spanning topical creams applied at home to outpatient procedures to formal surgery. The best choice depends on the location, the size of the patch, whether there are multiple lesions, the patient’s health, and what cosmetic outcome matters to them.
Topical Medications
Two topical creams are commonly used. Fluorouracil (5-FU) is a chemotherapy agent applied directly to the skin, typically once or twice daily for several weeks. Clearance rates for Bowen’s disease with 5-FU range from about 27% to 85%, a wide spread that reflects differences in how long people use it and how compliant they are with the sometimes-unpleasant treatment course. Imiquimod, which stimulates the local immune system to attack abnormal cells, achieves clearance in roughly 73% to 88% of cases. Both creams predictably cause redness, itching, and soreness in the treated area; nearly all patients experience at least some side effects.16JAMA Dermatology. Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma: A Systematic Review These reactions are actually expected and, to some degree, a sign that the medication is working, but they can be enough to make patients stop treatment early, which drags down real-world cure rates.
Photodynamic Therapy
Photodynamic therapy (PDT) involves applying a light-sensitizing cream to the lesion, waiting for the abnormal cells to absorb it, and then exposing the area to a specific wavelength of light. The light activates the cream, generating reactive molecules that destroy the cancerous cells while largely sparing the normal surrounding tissue. A meta-analysis of randomized trials found that PDT achieved a higher lesion clearance rate than both 5-FU and cryotherapy.17PubMed. Efficacy of photodynamic therapy for the treatment of Bowen’s disease: An updated systematic review and meta-analysis of randomized controlled trials The cosmetic outcome tends to be good, with minimal scarring compared to surgical approaches.18PubMed Central. Photodynamic Therapy for the Treatment of Bowen’s Disease: A Review on Efficacy, Non-Invasive Treatment Monitoring, Tolerability, and Cosmetic Outcome
PDT has particular advantages when a patient has multiple Bowen’s disease patches. A case report described a patient with multiple lesions successfully treated with repeated PDT sessions, which avoided the scarring and joint-function problems that surgery might have caused and improved the patient’s daily quality of life.19PubMed. Successful treatment for multiple Bowen’s disease using photodynamic therapy: A case report The treatment can also be repeated if a patch comes back, making it especially practical for people who may develop new lesions over time.
Curettage and Cryotherapy
Curettage (scraping the lesion away under local anesthesia) and cryotherapy (freezing with liquid nitrogen) are older, widely available treatments. A head-to-head prospective study found that curettage was superior to cryotherapy for Bowen’s disease, particularly on the lower leg: curettage was associated with shorter healing times, less pain, fewer complications, and a lower recurrence rate.20PubMed. Comparison of cryotherapy with curettage in the treatment of Bowen’s disease: a prospective study The lower leg is a notoriously slow-healing area, especially in older adults with poor circulation, so a treatment that gets the wound closed faster has real practical value there. Cryotherapy remains an option for small lesions in accessible locations where a quick office procedure is preferred and the patient is not bothered by a somewhat higher chance of needing retreatment.
Surgical Excision and Mohs Surgery
Standard surgical excision, cutting the lesion out with a margin of normal-looking skin, offers the most definitive tissue examination and high cure rates. For cases where tissue conservation matters, such as lesions on the face, fingers, or genitals, Mohs micrographic surgery provides the highest degree of margin control. In a series of 270 Mohs-treated Bowen’s disease cases, the five-year recurrence rate was about 6%.21PubMed. Cutaneous squamous carcinoma in situ (Bowen’s disease): treatment with Mohs micrographic surgery Half of the cases in that series were already recurrent tumors that had failed prior treatment, which inflates the recurrence figure: first-time Mohs treatment for Bowen’s disease generally performs even better. The downside is cost and access; Mohs surgery requires a specially trained surgeon and is more time-consuming than topical or destructive treatments.
The Internal Cancer Controversy
For decades, a persistent idea circulated in dermatology that Bowen’s disease was a “marker” for hidden internal cancers, meaning that a person diagnosed with it should be screened for cancers of the lung, gastrointestinal tract, or urogenital system. This idea originated from early case series that seemed to show elevated rates of internal malignancy in patients with Bowen’s disease. The concern was amplified by the association with arsenic exposure, since arsenic is a known carcinogen for both skin and internal organs.
Population-based studies have thoroughly debunked this link. A cohort study calculated the relative risk of subsequent internal cancer among Bowen’s disease patients compared to the general population at 1.1, which is essentially no excess risk at all.22PubMed. The subsequent risk of internal cancer with Bowen’s disease. A population-based study A larger study of over 1,100 patients reached the same conclusion, finding no strong association between Bowen’s disease and subsequent internal cancers.23JAMA Dermatology. Bowen Disease and Risk of Subsequent Malignant Neoplasms: A Population-Based Cohort Study of 1147 Patients A matched case-control study was equally clear: the frequency of internal malignancies in Bowen’s disease patients was not significantly increased.24PubMed. Bowen’s disease and internal malignancy. A matched case-control study
The practical takeaway is that a Bowen’s disease diagnosis on its own does not call for CT scans or other internal cancer screening beyond what is recommended for the patient’s age and risk factors. The earlier reports that sparked the scare were likely biased by small sample sizes, referral patterns, and the confounding effect of arsenic exposure in specific populations. In arsenic-exposed patients specifically, the risk of internal cancers is driven by the arsenic itself, not by the Bowen’s disease as a signaling mechanism.
Genetic Clues and the UV Question
The molecular profile of Bowen’s disease reflects its diverse causes. Mutations in the p53 tumor-suppressor gene are found in roughly half of cases, but the pattern of those mutations can vary in revealing ways. A study of Bowen’s disease in Korean patients found that mutations clustered in a specific region of the gene (exon 5) rather than being scattered across the usual UV-associated hotspots. While about a third of the mutations did show the signature of UV damage, the clustering pattern suggested that another carcinogen, possibly arsenic, was at work in many cases.25PubMed. p53 gene mutations in Bowen’s disease in Koreans: clustering in exon 5 and multiple mutations Interestingly, when patients had multiple Bowen’s disease patches, each lesion carried different mutations, indicating that each patch arose independently rather than spreading from a single source. This is consistent with the idea that Bowen’s disease is a field effect: widespread carcinogen exposure (UV, arsenic, or HPV) creates a skin environment in which multiple independent patches of abnormal cells can develop over time.
Living with Bowen’s Disease on Sensitive Areas
Bowen’s disease on the genitals or around the anus raises distinct challenges that go beyond the clinical question of clearing the lesion. Treatment in these areas often requires wider excisions, and healing can be complicated by the location’s constant motion, moisture, and friction. A study evaluating long-term outcomes after repair of large skin defects from perianal Bowen’s disease and the related Paget’s disease found that while overall quality of life, measured against population norms, was not significantly diminished, patients who developed incontinence after treatment scored lower on measures of lifestyle, coping, and embarrassment.26PubMed. Long-term functional and quality of life outcomes of patients after repair of large perianal skin defects for Paget’s and Bowen’s disease The message for patients and surgeons is that functional preservation matters: choosing a treatment that is effective against the disease while minimizing structural damage to the surrounding tissue can make a meaningful difference in long-term comfort and daily function. Non-surgical treatments like PDT and topical creams are increasingly explored for genital and perianal Bowen’s disease precisely because they avoid the morbidity of large excisions in these sensitive areas.